Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer

Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation

(2012) P Starlinger et al.   BRITISH JOURNAL OF CANCER

Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: Results from a large treatment observational cohort study

(2012) Fairooz F. Kabbinavar et al.   EUROPEAN JOURNAL OF CANCER

Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases

(2012) Anne E.M. van der Pool et al.   JOURNAL OF SURGICAL ONCOLOGY

Phase II Trial of Neoadjuvant Chemotherapy with XELOX plus Bevacizumab for Locally Advanced Rectal Cancer

(2011) K. Uehara et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case

(2011) Yoshiro Itatani et al.   SURGERY TODAY

Liver Resection Remains a Safe Procedure After Neoadjuvant Chemotherapy Including Bevacizumab

(2010) Dietmar Tamandl et al.   ANNALS OF SURGERY

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

(2009) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

Bevacizumab-Related Surgical Site Complication Despite Primary Tumor Resection in Colorectal Cancer Patients

(2009) Thierry Bège et al.   ANNALS OF SURGICAL ONCOLOGY

Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases

(2009) M. Klinger et al.   EJSO

Phase II Trial of Neoadjuvant Bevacizumab, Capecitabine, and Radiotherapy for Locally Advanced Rectal Cancer

(2009) Christopher H. Crane et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

(2009) Sanjaykumar Hapani et al.   LANCET ONCOLOGY

Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study

(2009) M. Kozloff et al.   ONCOLOGIST

Impact of Preoperative Bevacizumab on Complications After Resection of Colorectal Liver Metastases: Case-Matched Control Study

(2009) Mahfud Mahfud et al.   WORLD JOURNAL OF SURGERY

Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases

(2008) Susan B. Kesmodel et al.   JOURNAL OF CLINICAL ONCOLOGY

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

(2008) Bernard Nordlinger et al.   LANCET

“Spontaneous,” delayed colon and rectal anastomotic complications associated with bevacizumab therapy

(2007) David A. August et al.   JOURNAL OF SURGICAL ONCOLOGY

Addition of Bevacizumab to Irinotecan- and Oxaliplatin-Based Preoperative Chemotherapy Regimens Does Not Increase Morbidity after Resection of Colorectal Liver Metastases

(2007) Srinevas K. Reddy et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS